- Investing Ideas
- Swiss Biotech Stocks
Swiss Biotech Stocks
Results
15
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
15 companies
Roche Holding
Market Cap: CHF 261.5b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 328.10
7D
2.5%
1Y
24.9%
Novartis
Market Cap: CHF 226.2b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 118.54
7D
1.5%
1Y
26.4%
Galderma Group
Market Cap: CHF 37.4b
Operates as a dermatology company worldwide.
GALD
CHF 159.55
7D
0.8%
1Y
53.6%
Lonza Group
Market Cap: CHF 34.4b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 492.50
7D
3.9%
1Y
-12.8%
Sandoz Group
Market Cap: CHF 28.5b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 65.88
7D
-2.8%
1Y
63.3%
Bachem Holding
Market Cap: CHF 5.9b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 78.45
7D
2.1%
1Y
52.2%
Siegfried Holding
Market Cap: CHF 3.5b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 80.95
7D
1.0%
1Y
-15.6%
Tecan Group
Market Cap: CHF 1.8b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 145.10
7D
8.9%
1Y
-15.1%
Cosmo
Market Cap: CHF 1.3b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 79.00
7D
6.5%
1Y
45.5%
Kuros Biosciences
Market Cap: CHF 869.7m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 22.20
7D
7.2%
1Y
-11.2%
Basilea Pharmaceutica
Market Cap: CHF 668.1m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 53.90
7D
-2.4%
1Y
19.1%
Newron Pharmaceuticals
Market Cap: CHF 291.8m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 14.58
7D
1.0%
1Y
88.9%
Curatis Holding
Market Cap: CHF 118.0m
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
CURN
CHF 22.90
7D
-4.6%
1Y
127.9%
Xlife Sciences
Market Cap: CHF 117.7m
Focuses on the development and commercialization of research projects in the life sciences sector.
XLS
CHF 20.40
7D
1.5%
1Y
1.5%
Molecular Partners
Market Cap: CHF 109.2m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 2.92
7D
-3.0%
1Y
-11.5%